Login
Novavax NASDAQ: NVAX
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants
| Name | Novavax |
| Ticker | NVAX |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Clinical trial work |
|
Price
52W Low/High |
179.33
78.74 / 319.93 |
| Momentum | Neutral |
| Market cap | 13 B |
| 1Y Total Return |
25.32 %
Below Average |
| 1Y Volatility |
111.78 %
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants
Details
| Ticker | NVAX |
| Name | Novavax |
| ISIN | US6700024010 |
| CUSIP | 670002401 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Clinical trial work |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 07/30/2021
| Close Price | 179.33 |
| 52W Low/High | 78.74 / 319.93 |
| Market cap | 13 B |
| 1Y Total Return |
25.32 %
Below Average |
| 1Y Volatility |
111.78 %
High Risk |
| Beta | 0.05 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -66.9 % |
| Cash from Op. / Cur. Liabilities | 0.53 |
| Diluted Earnings / Share | -9.44 |
| ROE | - |
| ROIC | - |
| Price / Revenue | 14.2 |
| Price / Book | 12.6 |
| Price / CF | 20.3 |
| Current Ratio | 1.9 |
| Cur.Liabilities / Tot.Liabilities | 0.8 |
| Financial Leverage | 0.44 |
| in Mils USD |
rolling-year up to March
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
919
|
18
|
29
|
35
|
17
|
31
|
|
| Gross Profit |
919
|
18
|
29
|
35
|
17
|
31
|
|
| R&D |
1,323
|
95
|
165
|
175
|
207
|
203
|
|
| EBITDA |
-342
|
-97
|
-160
|
-163
|
-224
|
-201
|
|
| Operating Income |
-602
|
-103
|
-171
|
-174
|
-235
|
-208
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
73
|
44
|
20
|
17
|
14
|
14
|
|
| EPS exc. Extra |
-9.44
|
-4.09
|
-9.38
|
-12.16
|
-18.00
|
-15.80
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
2,608
|
328
|
221
|
276
|
362
|
593
|
|
| Cash, Eq & Invt ShortTerm |
2,031
|
245
|
109
|
164
|
240
|
470
|
|
| Total Current Assets |
2,247
|
255
|
123
|
181
|
258
|
485
|
|
| Total Non-Current Assets |
362
|
73
|
98
|
95
|
103
|
108
|
|
| Intangibles |
136
|
55
|
57
|
61
|
61
|
65
|
|
| Total Liabilities |
1,569
|
352
|
372
|
375
|
391
|
407
|
|
| Total Current Liabilities |
1,209
|
19
|
31
|
45
|
56
|
71
|
|
| Long Term Debt |
361
|
333
|
340
|
331
|
334
|
336
|
|
| Shareholder equity |
1,039
|
-24
|
-151
|
-99
|
-29
|
185
|
|
| Cash Flow | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
644
|
-109
|
-169
|
-166
|
-233
|
-165
|
|
| Depreciation |
253
|
5
|
8
|
10
|
9
|
7
|
|
| Cash from Investing |
-178
|
-38
|
27
|
82
|
172
|
-208
|
|
| Capex |
68
|
17
|
2
|
3
|
14
|
19
|
|
| Cash from Financing |
1,376
|
228
|
115
|
93
|
17
|
291
|
|
| Stock Issued |
1,326
|
228
|
115
|
93
|
17
|
15
|
|
| Debt (LT) Issued |
-108
|
0
|
0
|
-0
|
-0
|
324
|
|
| Free Cash Flow |
536
|
-180
|
-146
|
-96
|
-63
|
-355
|
|
| Ratios | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
1.9
|
13.4
|
3.9
|
4.0
|
4.6
|
6.8
|
|
| Financial Leverage D/E |
0.44
|
-
|
-
|
-
|
-
|
1.70
|
|
| Return on Capital Avg |
-
|
-99.0 %
|
-185.7 %
|
-124.2 %
|
-87.2 %
|
-75.6 %
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available